Trials and PIs
View all posts »ROCKET AF with Dr Kenneth Mahaffey
Nov 15, 2010 12:13 EST-
1Comments
-
Read later
Dr Kenneth Mahaffey (Duke University, Durham, NC) discusses Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation (ROCKET AF) with Dr Gabriel Steg.
Filmed during AHA 2010 in Chicago, IL on November 14.
See:
Off orbit? ROCKET AF: Rivaroxaban noninferior, but not superior, to warfarin in ITT analysis
Your comments
 |
 |
 |
||
 |
|
 |
||
 |
 |
 |
||
 |
|
|
 |
|
 |
 |
 |
||
 |
|
|
 |
|
|
|
|
||
|
||||
You must be a member (with full membership) to post a comment.
Already a member?
Enjoy all the benefits of theheart.org
With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.
Membership is free!
